Publicacions en què col·labora amb ALEJANDRO LUCÍA MULAS (28)

2019

  1. Muscle Fitness Cut Points for Early Assessment of Cardiovascular Risk in Children and Adolescents

    Journal of Pediatrics, Vol. 206, pp. 134-141.e3

2017

  1. Cardiorespiratory Fitness Cutoff Points for Early Detection of Present and Future Cardiovascular Risk in Children: A 2-Year Follow-up Study

    Mayo Clinic Proceedings, Vol. 92, Núm. 12, pp. 1753-1762

  2. Convergent validation of a questionnaire to assess the mode and frequency of commuting to and from school

    Scandinavian Journal of Public Health, Vol. 45, Núm. 6, pp. 612-620

2016

  1. Inflammatory biomarkers and academic performance in youth. The UP & DOWN Study

    Brain, Behavior, and Immunity, Vol. 54, pp. 122-127

  2. Perceived environment in relation to objective and self-reported physical activity in Spanish youth. The UP&DOWN study

    Journal of Sports Sciences, Vol. 34, Núm. 15, pp. 1423-1429

2015

  1. Objectively measured and self-reported leisure-time sedentary behavior and academic performance in youth: The UP&DOWN Study

    Preventive Medicine, Vol. 77, pp. 106-111

2014

  1. Are serotonergic system genes associated to smoking cessation therapy success in addition to CYP2A6 ?

    Pharmacopsychiatry, Vol. 47, Núm. 1, pp. 33-36

  2. Objective assessment of sedentary time and physical activity throughout the week in adolescents with Down syndrome: The UP&DOWN study

    Research in Developmental Disabilities, Vol. 35, Núm. 2, pp. 482-489

2011

  1. 'Smoking Genes': A genetic association study

    PLoS ONE, Vol. 6, Núm. 10

2010

  1. A novel, single algorithm approach to predict acenocoumarol dose based on CYP2C9 and VKORC1 allele variants

    PLoS ONE, Vol. 5, Núm. 6

  2. CYP2D6 polymorphism screening in a selected population of Spain (La Alpujarra): No effect of geographical isolation

    Annals of Human Biology, Vol. 37, Núm. 2, pp. 267-273

2009

  1. Pharmacogenetics of acenocoumarol: CYP2C9 *2 and VKORCI c.-l 639G>A, 497C>G, 1173C>T, and 3730G>A variants influence drug dose in anticoagulated patients

    Thrombosis and Haemostasis, Vol. 101, Núm. 3, pp. 591-593

2008

  1. Identification of CYP2D6 null variants among long-stay, chronic psychiatric inpatients: Is it strictly necessary?

    Human Psychopharmacology, Vol. 23, Núm. 6, pp. 533-536

2006

  1. ACTN3 genotype in professional endurance cyclists

    International Journal of Sports Medicine, Vol. 27, Núm. 11, pp. 880-884

2005

  1. PPARGC1A genotype (Gly482Ser) predicts exceptional endurance capacity in European men

    Journal of Applied Physiology, Vol. 99, Núm. 1, pp. 344-348

2004

  1. Mutations in the hereditary haemochromatosis gene HFE in professional endurance athletes

    British Journal of Sports Medicine, Vol. 38, Núm. 4, pp. 418-421

2002

  1. The response of sexual and stress hormones of male pro-cyclists during continuous intense competition

    International Journal of Sports Medicine, Vol. 23, Núm. 8, pp. 555-560

2001

  1. Hormone levels of world class cyclists during the tour of Spain stage race

    British Journal of Sports Medicine, Vol. 35, Núm. 6, pp. 424-430

  2. Plasma oxytocin during intense exercise in professional cyclists

    Hormone Research, Vol. 55, Núm. 3, pp. 155-159

  3. Thyroid hormone levels during a 3-week professional road cycling competition

    Hormone Research, Vol. 56, Núm. 5-6, pp. 159-164